{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:04:18Z","timestamp":1789596258291,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"DOI":"10.7759\/cureus.116374","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:39:37Z","timestamp":1789594777000},"source":"Crossref","is-referenced-by-count":0,"title":["RAS Mutations as Prognostic Biomarkers in Digestive Cancers: From Binary Classification to Variant-Specific and Context-Dependent Risk Stratification"],"prefix":"10.7759","author":[{"given":"Lucien","family":"Grados","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Rhaiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koceila","family":"Amroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Deguelte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Gigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Kianmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu378","article-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials","volume":"26","author":"Sorich MJ","year":"2015","unstructured":"Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015, 26:13-21. 10.1093\/annonc\/mdu378","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-025-00188-5","article-title":"KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts","volume":"3","author":"Osterlund E","year":"2025","unstructured":"Osterlund E, Ristim\u00e4ki A, Nunes L, et al.. KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts. BJC Rep. 2025, 3:72. 10.1038\/s44276-025-00188-5","journal-title":"BJC Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem E","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E, et al.. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009, 360:1408-1417. 10.1056\/NEJMoa0805019","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab190","article-title":"KRAS and BRAF mutations in stage II and III colon cancer: a systematic review and meta-analysis","volume":"114","author":"Formica V","year":"2022","unstructured":"Formica V, Sera F, Cremolini C, Riondino S, Morelli C, Arkenau HT, Roselli M. KRAS and BRAF mutations in stage II and III colon cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2022, 114:517-527. 10.1093\/jnci\/djab190","journal-title":"J Natl Cancer Inst"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17223599","article-title":"KRAS G12A identifies a high-risk subset in resected stage II-III colorectal cancer","volume":"17","author":"Momma T","year":"2025","unstructured":"Momma T, Okayama H, Hayashishita S, et al.. KRAS G12A identifies a high-risk subset in resected stage II-III colorectal cancer. Cancers (Basel). 2025, 17:3599. 10.3390\/cancers17223599","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0400","article-title":"Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations","volume":"23","author":"Cercek A","year":"2017","unstructured":"Cercek A, Braghiroli MI, Chou JF, et al.. Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations. Clin Cancer Res. 2017, 23:4753-4760. 10.1158\/1078-0432.CCR-17-0400","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9870","article-title":"Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases","volume":"102","author":"Brudvik KW","year":"2015","unstructured":"Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015, 102:1175-1183. 10.1002\/bjs.9870","journal-title":"Br J Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2015.0313","article-title":"Association between specific mutations in KRAS codon 12 and colorectal liver metastasis","volume":"150","author":"Margonis GA","year":"2015","unstructured":"Margonis GA, Kim Y, Spolverato G, et al.. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg. 2015, 150:722-729. 10.1001\/jamasurg.2015.0313","journal-title":"JAMA Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.53588","article-title":"KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma","volume":"8","author":"Norton C","year":"2025","unstructured":"Norton C, Shaw MS, Rubnitz Z, et al.. KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma. JAMA Netw Open. 2025, 8:e2453588. 10.1001\/jamanetworkopen.2024.53588","journal-title":"JAMA Netw Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.002","article-title":"Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer","volume":"42","author":"McIntyre CA","year":"2024","unstructured":"McIntyre CA, Grimont A, Park J, et al.. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell. 2024, 42:1614-1629.e5. 10.1016\/j.ccell.2024.08.002","journal-title":"Cancer Cell"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef A","year":"2024","unstructured":"Yousef A, Yousef M, Chowdhury S, et al.. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precis Oncol. 2024, 8:27. 10.1038\/s41698-024-00505-0","journal-title":"NPJ Precis Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262210908","article-title":"Clinical and molecular characteristics of KRAS codon-specific mutations in advanced pancreatic ductal adenocarcinoma with prognostic and therapeutic implications","volume":"26","author":"Cho D","year":"2025","unstructured":"Cho D, Shin K, Hong TH, et al.. Clinical and molecular characteristics of KRAS codon-specific mutations in advanced pancreatic ductal adenocarcinoma with prognostic and therapeutic implications. Int J Mol Sci. 2025, 26:10908. 10.3390\/ijms262210908","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105827","article-title":"NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data","volume":"10","author":"Reichinger A","year":"2025","unstructured":"Reichinger A, Friedrich A, Lentner T, et al.. NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data. ESMO Open. 2025, 10:105827. 10.1016\/j.esmoop.2025.105827","journal-title":"ESMO Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.2_suppl.654","article-title":"Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced\/metastatic pancreatic duct adenocarcinoma (PDAC)","volume":"44","author":"Wainberg ZA","year":"2026","unstructured":"Wainberg ZA, Henry JT, Park H, et al.. Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced\/metastatic pancreatic duct adenocarcinoma (PDAC). J Clin Oncol. 2026, 44:654. 10.1200\/JCO.2026.44.2_suppl.654","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer","volume":"395","author":"O'Reilly EM","year":"2026","unstructured":"O'Reilly EM, Wainberg ZA, Hendifar AE, et al.. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026, 395:325-337. 10.1056\/NEJMoa2605555","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese AM","year":"2025","unstructured":"Varghese AM, Perry MA, Chou JF, et al.. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat Med. 2025, 31:466-477. 10.1038\/s41591-024-03362-3","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma","volume":"157","author":"Zhou SL","year":"2022","unstructured":"Zhou SL, Xin HY, Sun RQ, et al.. Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma. JAMA Surg. 2022, 157:59-65. 10.1001\/jamasurg.2021.5679","journal-title":"JAMA Surg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105306","article-title":"Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers","volume":"10","author":"Iida K","year":"2025","unstructured":"Iida K, Matsui Y, Urabe Y, Muramatsu T, Matsuzaki J, Saito Y. Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers. ESMO Open. 2025, 10:105306. 10.1016\/j.esmoop.2025.105306","journal-title":"ESMO Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.9840","article-title":"KRAS allelic variants in biliary tract cancers","volume":"7","author":"Moffat GT","year":"2024","unstructured":"Moffat GT, Hu ZI, Meric-Bernstam F, et al.. KRAS allelic variants in biliary tract cancers. JAMA Netw Open. 2024, 7:e249840. 10.1001\/jamanetworkopen.2024.9840","journal-title":"JAMA Netw Open"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00263","article-title":"KRAS variants are associated with survival outcomes and genomic alterations in biliary tract cancers","volume":"8","author":"Gelfer R","year":"2024","unstructured":"Gelfer R, Gulla A, Kalvin HL, et al.. KRAS variants are associated with survival outcomes and genomic alterations in biliary tract cancers. JCO Precis Oncol. 2024, 8:e2400263. 10.1200\/PO.24.00263","journal-title":"JCO Precis Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2022.03.005","article-title":"Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma","volume":"48","author":"Procopio F","year":"2022","unstructured":"Procopio F, Branciforte B, Nappo G, Di Tommaso L, Lleo A, Torzilli G. Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma. Eur J Surg Oncol. 2022, 48:1455-1463. 10.1016\/j.ejso.2022.03.005","journal-title":"Eur J Surg Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.21873\/cgp.20492","article-title":"KRAS mutations in cholangiocarcinoma: prevalence, prognostic value, and KRAS G12\/G13 detection in cell-free DNA","volume":"22","author":"Thongyoo P","year":"2025","unstructured":"Thongyoo P, Chindaprasirt J, Aphivatanasiri C, et al.. KRAS mutations in cholangiocarcinoma: prevalence, prognostic value, and KRAS G12\/G13 detection in cell-free DNA. Cancer Genomics Proteomics. 2025, 22:112-126. 10.21873\/cgp.20492","journal-title":"Cancer Genomics Proteomics"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03966-7","article-title":"KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer","volume":"149","author":"Shimozaki K","year":"2023","unstructured":"Shimozaki K, Shinozaki E, Yamamoto N, et al.. KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. J Cancer Res Clin Oncol. 2023, 149:1273-1283. 10.1007\/s00432-022-03966-7","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.96","article-title":"Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy","volume":"7","author":"Matsusaka S","year":"2016","unstructured":"Matsusaka S, Kobunai T, Yamamoto N, et al.. Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy. Genes Cancer. 2016, 7:27-35. 10.18632\/genesandcancer.96","journal-title":"Genes Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-271","article-title":"Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer","volume":"7","author":"Takahashi N","year":"2014","unstructured":"Takahashi N, Yamada Y, Taniguchi H, et al.. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes. 2014, 7:271. 10.1186\/1756-0500-7-271","journal-title":"BMC Res Notes"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06996-x","article-title":"Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas","volume":"20","author":"Rehkaemper J","year":"2020","unstructured":"Rehkaemper J, Korenkov M, Quaas A, et al.. Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas. BMC Cancer. 2020, 20:587. 10.1186\/s12885-020-06996-x","journal-title":"BMC Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2025.2610630","article-title":"Prognostic value of KRAS gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis","volume":"61","author":"Aslani S","year":"2026","unstructured":"Aslani S, Lee B, Strickland AH, Shen H, Croagh D. Prognostic value of KRAS gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Scand J Gastroenterol. 2026, 61:352-362. 10.1080\/00365521.2025.2610630","journal-title":"Scand J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510833-ras-mutations-as-prognostic-biomarkers-in-digestive-cancers-from-binary-classification-to-variant-specific-and-context-dependent-risk-stratification","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:39:38Z","timestamp":1789594778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510833-ras-mutations-as-prognostic-biomarkers-in-digestive-cancers-from-binary-classification-to-variant-specific-and-context-dependent-risk-stratification"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.116374","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}